News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
291,387 Results
Type
Article (15889)
Company Profile (281)
Press Release (275217)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (82703)
Career Advice (193)
Deals (13699)
Drug Delivery (37)
Drug Development (60971)
Employer Resources (35)
FDA (6543)
Job Trends (5709)
News (158816)
Policy (11192)
Tag
Academia (967)
Accelerated approval (3)
Adcomms (12)
Allergies (69)
Alliances (22456)
ALS (75)
Alzheimer's disease (946)
Antibody-drug conjugate (ADC) (111)
Approvals (6577)
Artificial intelligence (137)
Autoimmune disease (20)
Automation (5)
Bankruptcy (106)
Best Places to Work (5151)
BIOSECURE Act (6)
Biosimilars (47)
Biotechnology (232)
Bladder cancer (67)
Brain cancer (25)
Breast cancer (184)
Cancer (1674)
Cardiovascular disease (136)
Career advice (170)
Career pathing (3)
CAR-T (128)
Cell therapy (354)
Cervical cancer (13)
Clinical research (50715)
Collaboration (590)
Compensation (289)
Complete response letters (15)
COVID-19 (1238)
CRISPR (44)
C-suite (177)
Cystic fibrosis (90)
Data (1854)
Denatured (11)
Depression (38)
Diabetes (168)
Diagnostics (1347)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (88)
Drug pricing (31)
Drug shortages (4)
Duchenne muscular dystrophy (94)
Earnings (32041)
Editorial (19)
Employer branding (4)
Employer resources (32)
Events (51459)
Executive appointments (480)
FDA (7397)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (527)
Gene editing (104)
Generative AI (10)
Gene therapy (280)
GLP-1 (441)
Government (1234)
Grass and pollen (4)
Guidances (72)
Healthcare (7063)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (110)
Indications (22)
Infectious disease (1319)
Inflammatory bowel disease (129)
Inflation Reduction Act (8)
Influenza (24)
Intellectual property (73)
Interviews (24)
IPO (7573)
IRA (13)
Job creations (900)
Job search strategy (161)
Kidney cancer (8)
Labor market (9)
Layoffs (233)
Leadership (3)
Legal (1499)
Liver cancer (38)
Lung cancer (231)
Lymphoma (115)
Machine learning (5)
Management (10)
Manufacturing (151)
MASH (66)
Medical device (2770)
Medtech (2771)
Mergers & acquisitions (6477)
Metabolic disorders (479)
Multiple sclerosis (63)
NASH (14)
Neurodegenerative disease (78)
Neuropsychiatric disorders (26)
Neuroscience (1419)
NextGen: Class of 2025 (2118)
Non-profit (897)
Now hiring (22)
Obesity (239)
Opinion (110)
Ovarian cancer (77)
Pain (64)
Pancreatic cancer (64)
Parkinson's disease (138)
Partnered (8)
Patents (145)
Patient recruitment (90)
Peanut (44)
People (26090)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (17657)
Phase II (23289)
Phase III (15010)
Pipeline (1016)
Policy (52)
Postmarket research (1190)
Preclinical (6510)
Press Release (30)
Prostate cancer (73)
Psychedelics (35)
Radiopharmaceuticals (220)
Rare diseases (323)
Real estate (1467)
Recruiting (14)
Regulatory (9724)
Reports (16)
Research institute (1001)
Resumes & cover letters (18)
Rett syndrome (5)
RNA editing (5)
RSV (18)
Schizophrenia (69)
Series A (104)
Series B (66)
Service/supplier (1)
Sickle cell disease (42)
Special edition (12)
Spinal muscular atrophy (125)
Sponsored (15)
Startups (2014)
State (1)
Stomach cancer (5)
Supply chain (24)
Tariffs (13)
The Weekly (37)
Vaccines (332)
Venture capitalists (32)
Weight loss (138)
Women's health (15)
Worklife (2)
Date
Today (152)
Last 7 days (661)
Last 30 days (1964)
Last 365 days (20918)
2025 (7582)
2024 (22143)
2023 (24158)
2022 (28783)
2021 (29834)
2020 (25118)
2019 (17591)
2018 (12924)
2017 (15059)
2016 (12869)
2015 (15442)
2014 (11235)
2013 (8157)
2012 (8265)
2011 (8393)
2010 (8134)
Location
Africa (173)
Alabama (44)
Alaska (2)
Arizona (67)
Arkansas (5)
Asia (18936)
Australia (3321)
California (4304)
Canada (1255)
China (404)
Colorado (159)
Connecticut (169)
Delaware (129)
Europe (41617)
Florida (542)
Georgia (134)
Idaho (17)
Illinois (250)
India (11)
Indiana (118)
Iowa (2)
Japan (90)
Kansas (64)
Kentucky (7)
Louisiana (3)
Maine (11)
Maryland (515)
Massachusetts (3438)
Michigan (76)
Minnesota (160)
Mississippi (1)
Missouri (24)
Montana (15)
Nebraska (5)
Nevada (23)
New Hampshire (16)
New Jersey (1147)
New Mexico (12)
New York (1172)
North Carolina (591)
North Dakota (5)
Northern California (1929)
Ohio (118)
Oklahoma (9)
Oregon (22)
Pennsylvania (857)
Puerto Rico (7)
Rhode Island (20)
South America (243)
South Carolina (5)
Southern California (1638)
Tennessee (26)
Texas (513)
United States (14928)
Utah (65)
Virginia (90)
Washington D.C. (32)
Washington State (404)
West Virginia (1)
Wisconsin (17)
291,387 Results for "tolerance therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients
May 7, 2025
·
6 min read
Press Releases
Topas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by its Proprietary Nanoparticle Platform in Frontiers in Immunology
March 17, 2025
·
3 min read
Press Releases
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
April 30, 2025
·
6 min read
Press Releases
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
October 23, 2024
·
6 min read
Press Releases
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
February 11, 2025
·
3 min read
Press Releases
Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
May 12, 2025
·
6 min read
Press Releases
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
December 18, 2024
·
3 min read
Bio NC
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the presentation of mature Phase 2 clinical trial results describing the positive impact of trilaciclib in combination with a TROP2 ADC on overall survival and tolerability compared to SG alone based on historical data from the ASCENT trial1.
May 28, 2024
·
11 min read
Drug Development
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
September 19, 2024
·
8 min read
Pharm Country
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax® Pharmaceuticals, Inc., a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and anti-viral barrier indications, announced results for a Maximum Tolerated Dose study in Sprague-Dawley Rats for Probudur™.
April 30, 2024
·
6 min read
1 of 29,139
Next
